A phase I, open label, cohort study of two doses of Cavatak (coxsackievirus type A21) [CVA 21] given intratumourally in stage IV melanoma patients
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs CVA 21 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 19 Jan 2010 CVA 21 is adequately tolerated according to results reported in a Viralytics media release.
- 22 Sep 2009 Status changed from active, no longer recruiting to completed; according to a viralytics media release.
- 13 Aug 2009 Status changed from recruiting to active, no longer recruiting, according to a Viralytics media release.